Chun-yan Sun
Union Hospital
Wuhan, 430022, China
Wuhan, 430022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma.
Journal: Journal of translational medicine
Published: July 08, 2025
LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma.
Journal: Biochemical pharmacology
Published: January 18, 2025
LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma.
Journal: Haematologica
Published: October 24, 2024
Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD.
Journal: Blood advances
Published: May 20, 2024
Advances in nano-immunotherapy for hematological malignancies.
Journal: Experimental hematology & oncology
Published: November 25, 2023
RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.
Journal: Cancer letters
Published: September 01, 2023
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease.
Journal: Leukemia
Published: April 21, 2023
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Journal: The Lancet regional health. Western Pacific
Published: November 04, 2022
Ferroptosis in hematological malignancies and its potential network with abnormal tumor metabolism.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 15, 2022
Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Journal: Circulation
Published: September 10, 2021
Last Updated: 09/26/2026